Patents by Inventor Bertram Müller-Myhsok

Bertram Müller-Myhsok has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for predicting a treatment response to a CRHR1 antagonist and/or a Vantagonist in a patient with depressive and/or anxiety symptoms
    Patent number: 10837062
    Abstract: A method of treating a human patient with depressive and/or anxiety symptoms which includes administering an effective amount of a V1B receptor antagonist and/or CRHR1 antagonist to the patient in need thereof, wherein the patient's genome has certain polymorphoric variants.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: November 17, 2020
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Florian Holsboer, Bertram Müller-Myhsok
  • METHOD FOR PREDICTING A TREATMENT RESPONSE TO A CRHR1 ANTAGONIST AND/OR A V1B ANTAGONIST IN A PATIENT WITH DEPRESSIVE AND/OR ANXIETY SYMPTOMS
    Publication number: 20190194752
    Abstract: A method of treating a human patient with depressive and/or anxiety symptoms which includes administering an effective amount of a V1B receptor antagonist and/or CRHR1 antagonist to the patient in need thereof, wherein the patient's genome has certain polymorphoric variants.
    Type: Application
    Filed: December 21, 2018
    Publication date: June 27, 2019
    Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Florian Holsboer, Bertram Müller-Myhsok
  • Method for predicting a treatment response to a CRHR1 antagonist and/or a V1B antagonist in a patient with depressive and/or anxiety symptoms
    Patent number: 10190168
    Abstract: The present invention relates to a method for predicting a treatment response to a corticotropin releasing hormone receptor type 1 (CRHR1) antagonist and/or a vasopressin receptor 1B (V1B) antagonist in a patient with depressive and/or anxiety symptoms. The present invention furthermore relates to a V1B receptor antagonist and/or CRHR1 antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in a patient. Also, kits, diagnostic compositions, devices and microarrays allowing the determination of the presence or absence of at least one polymorphic variant in the AVPR1B gene in combination with the presence or absence of at least one polymorphic variant in the patient's genome excluding the AVPR1B gene in the nucleic acid sample are described.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: January 29, 2019
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V.
    Inventors: Florian Holsboer, Bertram Müller-Myhsok
  • Polymorphisms in ABCB1 associated with a lack of clinical response to medicaments
    Patent number: 9901582
    Abstract: The present invention relates to methods, compositions, kits and reagents for determining the prognosis of a clinical response in a human patient to a medicament which acts in the central nervous system (CNS) and which is a substrate of the ABCB1 protein. Further, the invention relates to a combination of medicaments for the treatment of human patients having specific polymorphisms in the ABCB1 gene.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: February 27, 2018
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e. V.
    Inventors: Manfred Uhr, Florian Holsboer, Bertram Müller-Myhsok
  • METHOD FOR PREDICTING A TREATMENT RESPONSE TO A CRHR1 ANTAGONIST AND/OR A V1B ANTAGONIST IN A PATIENT WITH DEPRESSIVE AND/OR ANXIETY SYMPTOMS
    Publication number: 20160153043
    Abstract: The present invention relates to a method for predicting a treatment response to a corticotropin releasing hormone receptor type 1 (CRHR1) antagonist and/or a vasopressin receptor 1B (V1B) antagonist in a patient with depressive and/or anxiety symptoms. The present invention furthermore relates to a V1B receptor antagonist and/or CRHR1 antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in a patient. Also, kits, diagnostic compositions, devices and microarrays allowing the determination of the presence or absence of at least one polymorphic variant in the AVPR1B gene in combination with the presence or absence of at least one polymorphic variant in the patient's genome excluding the AVPR1B gene in the nucleic acid sample are described.
    Type: Application
    Filed: June 16, 2014
    Publication date: June 2, 2016
    Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Florian HOLSBOER, Bertram MÜLLER-MYHSOK
  • NEW POLYMORPHISMS IN ABCB1 ASSOCIATED WITH A LACK OF CLINICAL RESPONSE TO MEDICAMENTS
    Publication number: 20160067262
    Abstract: The present invention relates to methods, compositions, kits and reagents for determining the prognosis of a clinical response in a human patient to a medicament which acts in the central nervous system (CNS) and which is a substrate of the ABCB1 protein. Further, the invention relates to a combination of medicaments for the treatment of human patients having specific polymorphisms in the ABCB1 gene.
    Type: Application
    Filed: July 16, 2015
    Publication date: March 10, 2016
    Applicant: Max-Planck-Gesellschaft zur Förderung der Wisenschaften e. V.
    Inventors: Manfred Uhr, Florian Holsboer, Bertram Müller-Myhsok
  • GENETIC PREDICTORS OF RESPONSE TO TREATMENT WITH CRHR1 ANTAGONISTS
    Publication number: 20150278438
    Abstract: The invention relates inter alia to methods for predicting the response of patients with depressive symptoms and/or anxiety symptoms to treatment with a CRHR1 antagonist, and algorithms, kits, microarrays, probes and or/primers for use in such methods.
    Type: Application
    Filed: April 23, 2013
    Publication date: October 1, 2015
    Inventors: Bertram Müller-Myhsok, Elisabeth Binder, Florian Holsboer
  • Polymorphisms in ABCB1 associated with a lack of clinical response to medicaments
    Patent number: 9115398
    Abstract: The present invention relates to methods, compositions, kits and reagents for determining the prognosis of a clinical response in a human patient to a medicament which acts in the central nervous system (CNS) and which is a substrate of the ABCB1 protein. Further, the invention relates to a combination of medicaments for the treatment of human patients having specific polymorphisms in the ABCB1 gene.
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: August 25, 2015
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wisenschaften e.V.
    Inventors: Manfred Uhr, Florian Holsboer, Bertram Müller-Myhsok
  • Methods for Predicting an Antibody Response to Interferon Therapy in Multiple Sclerosis Patients
    Publication number: 20130252822
    Abstract: The present invention relates to a method of diagnosing a predisposition of a multiple sclerosis patient to become less susceptible or resistant to treatment with interferon ?, said method comprising determining in a sample obtained from said patient the presence of one or more SNP(s) selected from the group consisting of SNPs defined by the sequences of SEQ ID NOs 12, 17, 2, 3, 5, 7, 8, 1, 4, 6, 9, 10, 11, 13, 14, 15 and 16, wherein the presence of one or more of said SNP(s) in said sample is indicative for said predisposition.
    Type: Application
    Filed: April 20, 2011
    Publication date: September 26, 2013
    Inventors: Frank Weber, Bertram Müller-Myhsok, Florian Holsboer, Bernhard Hemmer
  • Polymorphisms in ABCB1 associated with a lack of clinical response to medicaments
    Patent number: 8030033
    Abstract: The present invention relates to methods, compositions and kits for determining the prognosis of a clinical response in a human patient to a medicament which acts in the central nervous system and which is a substrate of the ABCB1 protein. Further, the invention relates to a combination of medicaments for the treatment of human patients having specific polymorphisms in the ABCB1 gene.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: October 4, 2011
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenshaften e.V.
    Inventors: Manfred Uhr, Florian Holsboer, Elisabeth Binder, Bertram Mueller-Myhsok
  • USE OF POLYMORPHISMS IN THE TMEM132D GENE IN THE PREDICTION AND TREATMENT OF ANXIETY DISORDERS
    Publication number: 20100216653
    Abstract: The present invention relates to methods, compositions, kits and reagents for the diagnosis and treatment of anxiety disorders.
    Type: Application
    Filed: October 2, 2008
    Publication date: August 26, 2010
    Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V
    Inventors: Bertram Mueller-Myhsok, Angelika Erhardt, Manfred Uhr, Thomas Bettecken, Florian Holsboer
  • USE OF GENE VARIANTS OF THE HUMAN MEIS1, BTBD9, MAP2K5, LBXCOR1, PTPRD OR A2BP1 GENE FOR DIAGNOSTIC AND THERAPEUTIC APPROACHES TO RESTLESS LEGS SYNDROME (RLS)
    Publication number: 20100202972
    Abstract: The present invention relates to an oligo- or polynucleotide which can be used in the diagnosis and therapy of restless legs syndrome (RLS). Furthermore, the invention relates to methods of diagnosing a predisposition for or RLS and a method for selecting a therapy to prevent and treat RLS. Moreover, a method for determining the dose of a drug used for treating a patient suffering from RLS and a method to test the efficacy of a drug used for treating RLS in treating other dopaminergic diseases, sleep disorders or spinocerebellar ataxias as well as the use of a drug effective in treating RLS for testing the efficacy of said drug in treating other dopaminergic diseases, sleep disorders or spinocerebellar ataxias.
    Type: Application
    Filed: April 7, 2008
    Publication date: August 12, 2010
    Inventors: Juliane Winkelmann, Bertram Müller-Myhsok
  • POLYMORPHISMS IN ABCB1 ASSOCIATED WITH A LACK OF CLINICAL RESPONSE TO MEDICAMENTS
    Publication number: 20100184742
    Abstract: The present invention relates to methods, compositions, kits and reagents for determining the prognosis of a clinical response in a human patient to a medicament which acts in the central nervous system (CNS) and which is a substrate of the ABCB1 protein. Further, the invention relates to a combination of medicaments for the treatment of human patients having specific polymorphisms in the ABCB1 gene.
    Type: Application
    Filed: June 12, 2008
    Publication date: July 22, 2010
    Inventors: Manfred Uhr, Florian Holsboer, Bertram Müller-Myhsok
  • Polymorphisms in Abcb1 Associated with a Lack of Clinical Response to Medicaments
    Publication number: 20080064609
    Abstract: The present invention relates to methods, compositions and kits for determining the prognosis of a clinical response in a human patient to a medicament which acts in the central nervous system and which is a substrate of the ABCB1 protein. Further, the invention relates to a combination of medicaments for the treatment of human patients having specific polymorphisms in the ABCB1 gene.
    Type: Application
    Filed: May 12, 2005
    Publication date: March 13, 2008
    Applicant: Max-Planck-Gesellschft Zur Foerderung Der Wissenschaften e.V.
    Inventors: Manfred Uhr, Florian Holsboer, Elisabeth Binder, Bertram Mueller-Myhsok